Anteris Technologies Closes $88.8 Million U.S. IPO
Anteris Technologies Global Corp. (“ATGC” or “Anteris”) has successfully closed its initial public offering (IPO) of 14,800,000 shares of its common stock in the U.S., priced at $6.00 per share. The offering grossed approximately $88.8 million ($A 138.4 million) before…
Children’s Hospital Los Angeles Enhances Minimally Invasive Procedures with Virtual Reality
If the word “injection” causes your heart rate to rise, you’re not alone. One in four adults experience a fear of needles, often linked to childhood experiences. Children who frequently visit the hospital can experience significant anxiety about even routine…
Omnichannel Lens Uses AI and Behavioral Science for Precise, Personalized Messaging
Trinity Life Sciences, a leader in strategy, insights, and analytics for the life sciences sector, has launched a dedicated Marketing Communications Insights (MarCom Insights) Center of Excellence (COE). This COE evaluates pre- and post-launch educational and marketing materials aimed at…
HeartBeam Wins FDA Clearance for At-Home Heart Monitoring Tech
HeartBeam, Inc. (NASDAQ: BEAT), a company dedicated to revolutionizing cardiac care, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its HeartBeam system for comprehensive arrhythmia assessment. The HeartBeam device, featuring a patented design,…
EquipX Partners with Vizient to Enhance Healthcare Equipment Management
EquipX, a leader in AI-driven equipment management solutions, has partnered with Vizient, the largest healthcare performance improvement company in the U.S., to enhance healthcare equipment procurement and management. This collaboration aims to optimize fleet management, improving efficiency and performance across…
First-In-Human Study Shows Potential of Reprieve System in Acute Heart Failure
Reprieve Cardiovascular, Inc., a company focused on developing treatments for acute decompensated heart failure (ADHF), announced today the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device therapies in heart failure) conference in Frankfurt, Germany. The study…
Adagio Medical Appoints Todd Usen as CEO and Director
Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies for treating cardiac arrhythmias, announced today that founder Olav Bergheim has stepped down as Chief Executive Officer (CEO) and Chairperson of the Board of Directors, effective December 13,…
First Pancreatic Tumor Patients Treated with HistoSonics Edison® in GANNON Trial
HistoSonics, the maker of the Edison® Histotripsy System, announced the successful treatment of the first pancreatic tumor patients in its GANNON trial. This feasibility study aims to assess the safety of histotripsy, a cutting-edge non-invasive technology that uses focused ultrasound…
Fluid Biomed Raises $27M for Bioabsorbable Brain Aneurysm Stent
Fluid Biomed Inc., a clinical-stage medical device company focused on developing lifesaving solutions for vascular disease patients, has successfully raised $27 million in an oversubscribed Series A funding round. The financing was co-led by Amplitude Ventures and a major undisclosed…
NeoPhore Names Michael Shih CEO
NeoPhore Limited, a company specializing in small molecule neoantigen immuno-oncology therapies, has appointed Michael Shih as its Chief Executive Officer (CEO) and as a member of the Board of Directors, effective immediately. This appointment marks a significant milestone as the…
Gerresheimer: FDA Grants Tentative Approval for Lasix® ONYU
Gerresheimer, a leading provider of innovative systems and solutions for the pharma, biotech, and cosmetics industries, announced that the U.S. Food and Drug Administration (FDA) has granted Tentative Approval for SQ Innovation’s Lasix® ONYU. This product is designed for home…
SINOVAC Launches Phase III Trial for Bivalent HFMD Vaccine
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading biopharmaceutical provider in China, has announced the initiation of a Phase III clinical trial for its bivalent vaccine candidate, designed to prevent Hand, Foot, and Mouth Disease (HFMD) caused…